Mortality and Morbidity Reduction by Primary Percutaneous Coronary Intervention Is Independent of the Patient's Age  by de Boer, Sanneke P.M. et al.
M
P
I
S
C
P
R
D
O
p
B
d
M
t
f

t
c
c
R
i
m
t
o
w
C
n
a
C
F
H
N
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 3 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 1 1 . 0 2 2ortality and Morbidity Reduction by Primary
ercutaneous Coronary Intervention Is
ndependent of the Patient’s Age
anneke P. M. de Boer, MD,* Cynthia M. Westerhout, PHD,† R. John Simes, MD, PHD,‡
hristopher B. Granger, MD, PHD,** Felix Zijlstra, MD, PHD,†† Eric Boersma, PHD,* for the
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bjectives The aim of this study was to obtain a valid estimate of the clinical effects of primary
ercutaneous coronary intervention (PPCI) in relation to age.
ackground Treatment with PPCI is most beneﬁcial in high-risk myocardial infarction patients. Para-
oxically, elderly patients, who are at increased risk of adverse outcome, are often withheld PPCI.
ethods Individual patient data were obtained from 22 randomized trials (n  6,763) evaluating
he clinical effects of PPCI versus ﬁbrinolysis (FL). Differences in 30-day death, repeat myocardial in-
arction, and stroke between patients randomized to FL and PPCI were determined in 5 age-strata:
50, 50 to 60, 60 to 70, 70 to 80, and 80 years. Treatment effects are reported as odds ra-
ios (ORs) and 95% conﬁdence intervals (CI). Multivariable logistic regression analyses, which in-
luded age  treatment interaction, were applied to examine evidence of heterogeneity in age-spe-
iﬁc ORs.
esults Thirty-day death increased with increasing age and ranged from 1.1% (FL) and 1.8% (PPCI)
n patients 50 years to 26.4% and 18.3% in patients 80 years of age. The point estimate of treat-
ent effect (overall adjusted OR: 0.65; 95% CI: 0.52 to 0.79) was compatible with a mortality reduc-
ion favoring PPCI in all age-strata (except in patients 50 years of age), and 95% CIs were largely
verlapping. There was no evidence of heterogeneity in ORs between age categories. Similar results
ere observed for repeat myocardial infarction and stroke.
onclusions In this analysis of randomized trials, the reduction in clinical end points by PPCI was
ot inﬂuenced by age. Hence, age per se should not be considered an exclusion criterion for the
pplication of PPCI. (J Am Coll Cardiol Intv 2010;3:324–31) © 2010 by the American College of
ardiology Foundation
rom the *Erasmus Medical Center, Rotterdam, the Netherlands; †University of Alberta, Edmonton, Alberta, Canada; ‡National
ealth and Medical Research Council Clinical Trials Centre, Sydney, Australia; **Duke University Medical Center, Durham,
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325espite the dominant role of age in the prognosis of
oronary artery disease (CAD), elderly patients are often
xcluded from participation in clinical trials evaluating
fficacy and safety of cardiac treatment (1). The main reason
hy is that clinical trialists tend to favor the enrollment of
atients at low risk of potential side effects, and large
roportions of elderly patients meet 1 or more of the
ssociated exclusion criteria.
Because of the limited availability of clinical trial data and
he increasing variability in treatment response in relation to
ge, estimates of treatment effect in elderly CAD patients
eem to be uncertain for a broad variety of clinical situations.
articularly, uncertainty exists about the balance between
eneficial and harmful treatment effects, which hampers the
pplication of evidence-based treatment in clinical practice.
or example, the application of reperfusion therapy in
atients presenting with ST-segment elevation myocardial
nfarction (MI) is strongly related to age: elderly patients
ess often receive reperfusion therapy than their younger
ounterparts (2–4). Most likely the choice for conservative
reatment in elderly persons is based on negative perceptions
f the chances to reduce mortality risk due to limitation of
he infarct size (treatment benefit) relative to the chances to
ause harm. Particularly, the risk of severe disability or even
eath due to severe hemorrhagic complications is feared in
lderly patients receiving fibrinolytic (FL) therapy. Still, the
nderuse of reperfusion therapy in older MI patients is also
eported with respect to primary percutaneous coronary
ntervention (PPCI) (5). Apparently, in clinical practice,
here is a mismatch between (suspected) patient risk and
pplied treatment. This treatment-risk paradox has been
bserved in other settings in clinical cardiology as well (6,7).
The clinical outcome after PPCI as compared with FL in
lderly patients has been evaluated in the randomized trial
f de Boer et al. (8) (patients age 75 years) and in the
andomized SENIOR PAMI (Senior Primary Angioplasty
n Myocardial Infarction) trial (patients age 70 years) (9).
lthough de Boer et al. (8) demonstrated a favorable clinical
utcome after PPCI—a statistically significant reduction
as observed in the 30-day incidence of death, repeat
yocardial infarction (reMI), and stroke—the sample sizes
f both trials were too small to draw definite conclusions.
e recently pooled individual patient data from 22 clinical
rials of PPCI versus FL in patients with acute MI. This
eta-analytic dataset provides a unique and powerful op-
ortunity to study the clinical outcome of PPCI in relation
o age.
ethods
etails on the applied methodology of the pooled analysis
ave been published previously (10). In this section, we
riefly describe the trial selection and data collection pro- wess, end point definition, and data analysis for the current
tudy.
rial selection. All randomized trials that enrolled at least
0 patients presenting with MI assigned to treatment with
L or PPCI were considered. Trials published between
anuary 1990 and December 2002 were identified by OVID
EDLINE and ISI Web science with a broad range of key
ords. Each trial identified in this search was evaluated for
atient population, study treatment, protocol, and end
oints. The primary investigators of these studies were
ontacted for verification and access to the individual
atient data. In this way, 25 eligible trials were identified,
hich enrolled a total of 7,743 patients. Individual patient
ata were unavailable in 2 smaller trials (140 patients)
11,12), whereas the investigators of the larger CAPTIM
Comparison of Angioplasty and Prehospital Thrombolysis in
cute Myocardial Infarction) trial (n  840) elected not to
elease their data (13). Consequently, individual patient data
rom 22 trials (n  6,763) were pooled for the primary
nalysis. Table 1 presents the
ain design features of the in-
luded trials (8,14–34). Data were
ssessed for completeness and
nternal consistency with pub-
ished reports. Any discrepancies
etween analysis of the data pro-
ided and previously published
esults were queried and resolved
ith the primary investigator.
eﬁnitions of clinical end points.
he primary end point of this
ooled analysis was all-cause
ortality at 30 days after ran-
omization. Secondary end
oints included reMI and stroke
s well as the composite end points all-cause mortality or
eMI and all-cause mortality, reMI, or stroke. End points
ere counted until 30 days after randomization.
tatistical analysis. Summary statistics for all continuous
ariables are presented as medians with the corresponding
nterquartile range, and discrete variables are presented as
ounts and percentages. Patients were categorized according
o their age into 5 categories: 50, 50 to 60, 60 to 70,
70 to 80, and 80 years. Differences in baseline charac-
eristics in relation to age were evaluated by Kruskal-Wallis
ests or Mantel-Haenszel chi-square tests for trend, as
ppropriate.
All analyses of the relation between randomized treat-
ent and the incidence of clinical end points were performed
ccording to the intention-to-treat principle. Age-specific out-
ome data were pooled with the Cochrane-Mantel-Haenszel
ethod, and odds ratios (OR) and 95% confidence intervals
CI) for clinical end points are reported. Breslow-Day tests
Abbreviations
and Acronyms
CI  confidence interval
FL  fibrinolysis
ICH  intracranial
hemorrhage
MI  myocardial infarction
OR  odds ratio
PPCI  primary
percutaneous coronary
intervention
reMI  repeat myocardial
infarctionere applied to examine statistical evidence of heterogeneity
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326mong the age-specific ORs. The association between treat-
ent and the clinical end points in relation to age were also
valuated by logistic regression. First, crude ORs for study end
oints were determined on the basis of the single fixed effect
ogistic regression model, stratified by age-category. Subse-
uently, nonstratified models were fitted with age (as a con-
inuous variable), treatment, and the age  treatment interac-
ion term. To adjust for trial effects and for variations in the
tandards of practice across participating institutions, these
odels were then extended, taking study membership into
ccount. The final multivariable adjustment included study
embership, sex, body weight, diabetes mellitus, previous MI,
rior revascularization, anterior MI at presentation, heart rate,
ystolic blood pressure, and time to treatment.
Time to treatment was categorized into time from symp-
om onset to randomization (“presentation delay”) and time
Table 1. Key Design and Outcome Figures of the Trials That Are Included i
Trial or First Author
(Ref. #) Enrollment Inclusion Criteria
Symptom
Duration (h)
Streptokinase trials
Zijlstra (14) 1990–1992 ST1, 75 yrs 6
Ribeiro (15) 1989–1989 ST1, 75 yrs 6
Grinfeld (16) 1993–1995 ST1 12
Zijlstra (17) 1993–1995 ST1, low risk 6
Akhras (18) 1993–1995 ST1 12
Kedev (19) 1996 ST1 12
Prague-1 (20) 1997–1999 ST1, LBBB 6
de Boer (8) 1996–1999 ST1, 75 yrs 6
Prague-2 (21) 1999–2002 ST1 12
Duteplase trial
Gibbons (22) 1989–1991 ST1, 80 yrs 12
(Accelerated) tPA trials
Grines (23) 1990–1992 ST1 12
GUSTOIIb (24) 1995–1996 ST1, LBBB 12
JIMI (25) Published in 1997 ST1, 80 yrs 6
Ribichini (26) 1993–1996 Inferior/anterior
ST2, 80 yrs
6
Garcia (27) 1991–1996 Anterior MI 5
LIMI (28) 1995–1997 ST1, 80 yrs 6
STAT (29) 1997–1996 ST1, LBBB 12
STOPAMI-1 (30) 1997–1999 ST1 12
AIR PAMI (31) 1994–1999 70 yrs, anterior MI 12
C-PORT (32) 1996–1999 ST1 12
DANAMI-2 (33) 1997–2001 ST1 12
STOPAMI-2 (34) 1999–2001 ST1, LBBB 12
LBBB left bunch branch block; MImyocardial infarction; Not specified not specified in the m
angioplasty; ST1 ST-segment elevation; ST2 ST-segment depression; tPA tissue plasminogrom randomization to treatment (“treatment delay”). Per hefinition, the interval between randomization and the
ctual commencement of treatment is a post-randomization
ariable, which is influenced by allocated treatment. Hence,
nalyses in relation to treatment delay that are based on
bservations in individual patients can result in biased
stimates of treatment effect. Moreover, patients are ran-
omized to either FL or PPCI; so on a patient-level, time
o treatment can only be obtained for 1 strategy. Analyses
ased on observations on hospital level might help to
vercome this. Thus, the median time between randomiza-
ion and the start of treatment (i.e., first injection of the
brinolytic agent or the first balloon inflation) was calcu-
ated for each of the 153 participating hospitals. The
ospital-specific difference between these median times was
hen determined, which is hereafter referred to as “PCI-
elated delay,” and assigned to each patient within that
Analysis
Fibrinolysis
Primary PCI
atients
(n)
30-Day
Mortality (%)
Treatment in Case of
Persistent or
Recurrent Ischemia
Patients
(n)
30-Day
Mortality (%)
149 7.4 Not speciﬁed 152 1.3
50 6.0 Not speciﬁed 50 2.0
58 9.3 Not speciﬁed 54 13.8
53 2.1 Angiography ¡
possible
angioplasty
47 1.9
45 0.0 Not speciﬁed 42 8.9
67 10.4 Not speciﬁed 68 2.9
99 14.1 Not speciﬁed 101 6.9
41 22.0 Discretion cardiologist 46 6.5
421 10.0 Rescue PCI 429 6.8
56 3.6 Discretion cardiologist 47 4.3
200 6.5 Discretion cardiologist 195 3.1
573 7.0 Discretion cardiologist 565 5.7
62 1.6 Not speciﬁed 59 1.7
55 5.5 Emergency
catheterization ¡
rescue PTCA
55 1.8
94 10.6 Discretion cardiologist 95 3.2
75 6.7 Not speciﬁed 75 5.3
61 3.3 Discretion cardiologist 62 3.2
69 7.2 Not speciﬁed 71 4.2
66 12.1 Emergency
catheterization
71 8.5
226 7.1 Not speciﬁed 225 5.3
782 7.8 Not speciﬁed 790 6.6
81 6.2 Not speciﬁed 81 2.5
lts paper; PCI percutaneous coronary intervention; PTCA percutaneous transluminal coronary
vator.n This
P
ain resuospital. Consequently, PCI-related delay should be inter-
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327reted as the additional time that is needed to start the PCI
rocedure after treatment with a fibrinolytic agent could
ave been started.
All tests are 2-sided with a significance level of 0.05. All
tatistical analyses were performed with the SAS System
ersion 8.2 (SAS Institute, Inc., Cary, North Carolina).
esults
atients. This pooled analysis included 6,763 patients from
2 trials in which patients were randomized to FL (n 
,383) or PPCI (n  3,380). There were important differ-
nces in clinical baseline characteristics in relation to age
Table 2). Elderly patients had an unfavorable risk profile,
ecause they more often had diabetes mellitus, a history of
I, and a longer presentation delay. For example, 46% of
atients in the 50 years-age category were randomized
ithin 2 h after the onset of symptoms, in contrast to only
6% in those older than 80 years of age. Interestingly,
CI-related delay tended to decrease with age. We observed
statistically significant relation among admission systolic
lood pressure, heart rate, and age, but the difference in
edian values of these hemodynamic parameters between
ounger and elderly patients seemed clinically irrelevant.
linical end points. Overall, 446 (6.6%) patients died within
0 days of randomization. Mortality was significantly lower
n patients randomized to PPCI (n  178; 5.3%) than in
atients randomized to FL (n  268; 7.9%). Elderly
Table 2. Baseline Characteristics According to Age
<50 >50–60
No. of patients 1,231 1,757
Randomized to primary PCI, % 50 49
Men, % 90 84
Diabetes mellitus, % 11 14
Prior MI, % 9.7 13
Prior PTCA, % 4.3 5.5
Prior CABG, % 0.86 1.8
Anterior MI, % 47 45
Use of aspirin, % 51 54
Use of beta blocker, % 40 35
Use of heparin, % 88 90
Use of GP IIb/IIIa, % 23 26
Systolic blood pressure, mm Hg 133 (120–140) 133 (120–145)
Pulse, beats/min 76 (68–86) 76 (65–80)
Presentation delay, min 130 (90–195) 135 (87–195)
Presentation delay 2 h, % 46 45
PCI related delay, min 55 (37–73) 54 (37–74)
PCI related delay 0–35 min, % 22 22
Dichotomous data represent percentages; continuous data represent median values (interquartileCABG coronary artery bypass grafting; GP glycoprotein; other abbreviations as in Table 1.atients had higher mortality risk than younger patients,
rrespective of treatment (Table 3). Primary PCI was
ssociated with a lower incidence of death than FL
herapy in all age-categories, except in patients 50 years
f age (Table 3, Fig. 1). The Breslow-Day test for
omogeneity of ORs across age-categories was nonsig-
ificant (p  0.24), and interaction between age and
reatment was not statistically significant (p  0.73).
ence, there was no evidence that the observed mortality
eduction by PPCI was heterogeneous with respect to
ge. After multivariable adjustment, PPCI was associated
ith a 36% proportional reduction in the odds of death
ompared with FL therapy, irrespective of age (adjusted
R: 0.65; 95% CI: 0.52 to 0.79).
Repeat MI occurred in 225 (6.7%) patients who were
andomized to FL and in 80 (2.4%) of those randomized
o PPCI. A lower incidence of reMI in patients random-
zed to PPCI was consistently seen in all age-categories
Table 3, Fig. 1), and there was no evidence of hetero-
eneity in ORs (p  0.67). Primary PCI was associated
ith a 63% proportional reduction in the odds of reMI
adjusted OR: 0.37; 95% CI: 0.28 to 0.48) and a 49%
eduction in the composite end point of all-cause mor-
ality or reMI (adjusted OR: 0.51; 95% CI: 0.43 to 0.60),
rrespective of age.
Similar results were observed with respect to stroke,
hich occurred in 83 (2.6%) of the patients randomized to
L and in 48 (1.5%) of those randomized to PPCI.
ge Category, yrs
>60–70 >70–80 >80 p Value
1,938 1,427 410
51 49 49
73 63 48 0.001
17 17 16 0.001
13 16 18 0.001
4.8 4.5 3.2 0.43
2.5 3.1 1.6 0.002
45 47 52 0.32
54 59 66 0.001
32 33 38 0.047
89 89 82 0.11
24 27 20 0.62
133 (120–145) 133 (123–145) 133 (120–150) 0.022
76 (65–83) 76 (66–81) 76 (68–88) 0.001
143 (91–220) 156 (100–240) 180 (120–300) 0.001
40 36 26 0.001
54 (37–74) 56 (38–77) 52 (38–72) 0.030
22 18 17 0.026A
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328lthough the incidence of stroke was increased after PPCI
n patients younger than 50 years of age (Fig. 1C), the CI of
reatment effect was wide, and there was no evidence of
eterogeneity in ORs in relation to age (p  0.40). Primary
CI was systematically associated with a lower incidence of
he composite end point of all-cause mortality, reMI, or
troke in all age-categories, and again there was no evidence
f heterogeneity in ORs (p  0.35).
bsolute treatment effects. Figure 2 shows 30-day mortal-
ty in patients randomized to PPCI and FL (panel A) as
ell as the absolute mortality reduction by PPCI (panel B)
n relation to age as a continuous variable. Apparently, the
bsolute risk reduction was strongly and positively associ-
ted with age. For example, at age 60 years, PPCI was
ssociated with 1.4 fewer deaths/100 patients treated com-
ared with FL, whereas the risk reduction amounted to
.1/100 patients at age 80 years.
ctogenarians. Octogenarians (80 years of age) comprise
clinically relevant cohort and represented 6% of patients.
n this cohort, the patients who were randomized to PPCI
ad a lower incidence of mortality (26.4% vs. 18.3% events;
 0.049), reMI (7.0% vs. 3.9%; p  0.18), and stroke
7.9% vs. 5.8%; p  0.45) than their counterparts who were
andomized to FL. Statistical significance was not reached
or each of these end points, most likely due to small
Table 3. Effects of Allocated Treatment on the Incidence of Clinical End Po
Age C
<50 >50–60 >
All-cause mortality
Fibrinolysis, % 1.1 3.9
Primary PCI, % 1.8 2.1
Odds ratio (95% CI)* 1.6 (0.62–4.2) 0.53 (0.30–0.94) 0.72
Myocardial reinfarction
Fibrinolysis, % 5.3 6.4
Primary PCI, % 2.1 1.6
Odds ratio (95% CI)* 0.39 (0.20–0.74) 0.24 (0.13–0.44) 0.33
Stroke
Fibrinolysis, % 0.34 0.94
Primary PCI, % 0.52 0.74
Odds ratio (95% CI)* 1.5 (0.26–9.2) 0.78 (0.27–2.3) 0.64
All-cause mortality or reMI
Fibrinolysis, % 6.3 9.9
Primary PCI, % 3.8 3.6
Odds ratio (95% CI)* 0.58 (0.34–0.98) 0.34 (0.22–0.52) 0.55
All-cause mortality, reMI, or stroke
Fibrinolysis, % 6.6 10.8
Primary PCI, % 4.1 4.2
Odds ratio (95% CI)* 0.60 (0.36–1.0) 0.36 (0.24–0.53) 0.55
*Unadjusted odds ratio.
CI confidence interval; PCI percutaneous coronary intervention; reMI repeat myocardial inumbers. aiscussion
n this pooled analysis, which was based on randomized
rials that involved 6,763 MI patients, age did not modify
he mortality reduction by PPCI compared with FL ther-
py. Because age is a key determinant of mortality in MI
atients, the consequence of the consistent relative risk
eduction across all age groups is an increasing absolute risk
eduction with increasing age and a decreasing number of
atients that need to undergo PPCI (instead of FL therapy)
o prevent 1 death—the “number needed to treat”. Note-
orthy, PPCI was associated with significantly reduced
ortality in patients age 80 years or over. The estimated
umber needed to treat in these patients was only 20. In
iew of our results, age per se should not be considered an
xclusion criterion for the application of PPCI.
One of the most severe complications of FL therapy is the
isk of stroke, particularly intracranial hemorrhage (ICH).
his complication occurs in approximately 1% of patients
eceiving FL therapy, with a case-fatality of around 50%,
hereas one-half of the ICH victims who survive will
emain irreversibly disabled (35). Because age is 1 of the
trongest determinants of ICH risk after pharmacology-
ased reperfusion therapy (36), physicians tend to be quite
onservative in treating elderly persons. Indeed, in our data,
t 30-Day Follow-Up in Relation to Age
ry, yrs
p Value
Breslow-Day0 >70–80 >80 Any Age
14.8 26.4 0.25 7.9
8.7 18.3 5.3
.0) 0.55 (0.39–0.76) 0.62 (0.39–1.0) 0.63 (0.52–0.77)
0.67
8.2 7.0 6.7
3.2 3.9 2.4
.54) 0.37 (0.23–0.62) 0.53 (0.21–1.4) 0.34 (0.26–0.44)
0.40
5.7 7.9 2.6
2.2 5.8 1.5
.2) 0.36 (0.20–0.68) 0.72 (0.31–1.7) 0.57 (0.40–0.81)
0.37
20.8 30.3 13.5
11.4 19.8 7.3
.74) 0.49 (0.36–0.65) 0.57 (0.36–0.90) 0.49 (0.42–0.58)
0.35
24.2 35.1 15.3
12.5 23.3 8.3
.74) 0.45 (0.34–0.59) 0.56 (0.36–0.86) 0.49 (0.42–0.57)
n.ints a
atego
60–7
6.9
5.0
(0.49–1
6.9
2.4
(0.21–0
2.4
1.6
(0.33–1
12.5
7.2
(0.40–0
14.3
8.5
(0.41–0mong octogenarians who received FL, stroke risk was as
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329igh as 8%. We demonstrated that PPCI was associated
ith a reduced incidence of stroke. Importantly, the risk
eduction was particularly strong in elderly patients (al-
hough there was no evidence of heterogeneity in relative
troke reduction in relation to age). This observation pro-
ides another argument to not systematically exclude elderly
atients from treatment with PPCI.
We did not observe significant heterogeneity in treatment
ffect with respect to the specified outcome events. Indeed,
he CIs around the point estimates of treatment effect in the
age-categories were largely overlapping. Still, any hetero-
eneity cannot be excluded with complete certainty. Despite
he considerable amount of included patients, the applied
tatistical tests of heterogeneity lacked power to reveal small
ut clinically relevant differences. The true existence of such
ifferences is unlikely as far as death is concerned, because
oint estimates were quite consistent across age-groups.
owever, we acknowledge that age might be a modifier of
he influence of PPCI on the incidence of reMI (risk
eduction slightly decreases with age) and stroke (risk
eduction slightly increases with age). In fact, additional
andomized trials are needed to obtain more precise esti-
ates of treatment effects in strata according to age, but in
iew of the unambiguous results of the trials that have been
onducted, it is unlikely that such new trials will ever be
Figure 1. Incidence of Death, MI, Stroke/Treatment According to Age
Relation between allocated treatment (primary percutaneous coronary interven
tion (MI) (B), and stroke (C) at 30 days according to age category. Data represeonducted. AWe realize that elderly patients who are eligible to partici-
ate in a randomized trial might not be representative for
eal-world patients. Because elderly persons do not fit the
nclusion and exclusion criteria as younger patients, they are
ore likely to be excluded from participation in trials. Indeed,
ot only do elderly patients often suffer from comorbidities that
ormally exclude participation in most trials—such as demen-
ia, gastrointestinal bleeds, or malignancy—but clinicians also
re often reluctant to include the fragile elderly patient who
therwise doesn’t meet exclusion criteria. Thus, elderly persons
ho are included in trials form a selected group, more so than
ounger patients. Consequently, the observed favorable effects
n elderly persons probably will not fully be extrapolated to the
eneral population. We cannot overcome this issue in the
ontext of our pooled analysis.
The main strength of this study is that it is based on
andomized trials. Thus, although one might challenge the
xternal validity, the observed results are at least internally
alid (i.e., the results are valid for the type of patients that
ave entered the included trials). In this respect, the main
imitation of our analyses is that the CAPTIM trial data
ere not included. The CAPTIM trial strongly suggested
hat the strategy of (pre-hospital) FL, followed by a “rescue”
CI in case of persistent ischemia, might result in a
ortality reduction compared with the PPCI strategy in
atients presenting within 2 h after onset of symptoms.
PPCI] vs. ﬁbrinolysis [FL]) and the incidence of death (A), myocardial infarc-
justed odds ratios and 95% conﬁdence intervals.tion [lthough these results were not confirmed in the PCAT-2
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ain analysis (in fact, a statistically significant mortality
eduction was observed in favor of PPCI in patients pre-
enting within 2 h) (10), the inclusion of the CAPTIM data
ould have led to more precise estimates of treatment effect
n patients presenting early. This particularly affected
ounger patients, because they tend to present earlier than
lderly persons.
onclusions
n this pooled analysis of randomized clinical trials, there
as no evidence that the reduction in clinical end points by
PCI was influenced by age. Hence, age per se should not
e considered an exclusion criterion for the application of
PCI.
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